1. Girardi F, Frey Tirri B, Ku¨ppers V, et al. Neue kolposkopische IFCPC-Nomenklatur der Cervix uteri (Rio de Janeiro 2011). Frauenarzt 2012; 53: 1064–1065. Im Internet: https://www.ag-cpc.de/wp-content/uploads/2018/07/2012-11-Reich.pdf (letzter Zugriff: 01.08.2023).
2. AWMF. Evidenz- und konsensbasierte S3-Leitlinie Impfprävention HPV-assoziierter Neoplasien – Langfassung – AWMF-Register Nr.: 082-002, 2020 https://www.awmf.org/uploads/tx_szleitlinien/082-002l_S3_Impfpraevention-HPV-assoziierter-Neoplasien_2020-07_01.pdf (letzter Zugriff: 01.06.2023).
3. Bornstein J, et al. 2011 Colposcopic Terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2012; 120, 166–172.
4. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Chemoradiotherapy for cervical cancer: results of a meta-analysis. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010; (1):CD008285.
5. Colombo N., Dubot C., Lorusso D., et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 2021; 385: 1856–67.